Novel Therapeutic Approaches
![](/media-library/sites/phys-pharm-neuro/research-section/BeckFishScale_button_square.jpg)
Overview
We undertake a variety of approaches to improve outcomes in disease and dysfunction. These include:
- Targeting underlying molecular defects to reduce the risk of sudden death in patients with inherited cardiac arrhythmias.
- Molecular modelling and structural docking approaches to produce new compounds that selectively target ion channels in the central nervous system.
- Exploring the effectiveness and mode of action of small molecule activators to reverse urinary tract pathologies.
- Developing deep brain stimulation patterns to improve symptoms for patients with movement and non-movement related neurological disorders.
- Multidisciplinary approaches to improve anaesthesia, pain and critical care.
- Validating new and repurposed pharmacological agents for treatment of cardiovascular and psychiatric conditions.
Much of this work is done together with industry partners, clinicians and via research networks such as the Bristol Heart Institute.
Working in this area
- Dr Ana Paula Abdala Sheikh
- Dr Michael Ashby
- Dr Zuner Bortolotto
- Professor Mark Cannell
- Dr Petra Fischer
- Professor Christopher Fry
- Professor Jules Hancox
- Dr Stephen Harmer
- Dr James Hodge
- Dr Andrew James
- Eamonn Kelly
- Professor Neil Marrion
- Dr Valentina Mosienko
- Professor Stuart Mundell
- Dr Angus Nightingale
- Professor Tony Pickering
- Professor Emma Robinson
- Professor David Sheppard